Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Net Income towards Common Stockholders: 2012-2024

Historic Net Income towards Common Stockholders for Neurogene (NGNE) over the last 11 years, with Dec 2024 value amounting to -$75.7 million.

  • Neurogene's Net Income towards Common Stockholders fell 3.65% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.8 million, marking a year-over-year decrease of 23.93%. This contributed to the annual value of -$75.7 million for FY2024, which is 43.76% down from last year.
  • Per Neurogene's latest filing, its Net Income towards Common Stockholders stood at -$75.7 million for FY2024, which was down 43.76% from -$52.7 million recorded in FY2023.
  • Neurogene's Net Income towards Common Stockholders' 5-year high stood at -$52.7 million during FY2023, with a 5-year trough of -$75.7 million in FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$55.2 million (2022), whereas its average is -$61.2 million.
  • In the last 5 years, Neurogene's Net Income towards Common Stockholders grew by 4.58% in 2023 and then plummeted by 43.76% in 2024.
  • Yearly analysis of 3 years shows Neurogene's Net Income towards Common Stockholders stood at -$55.2 million in 2022, then climbed by 4.58% to -$52.7 million in 2023, then plummeted by 43.76% to -$75.7 million in 2024.